Viewing Study NCT00618657

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:45 PM
Ignite Modification Date: 2026-02-11 @ 6:08 PM
Study NCT ID: NCT00618657
Status: COMPLETED
Last Update Posted: 2024-02-28
First Post: 2008-02-07
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
Sponsor: University of California, Irvine
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
None HER2-negative Breast Cancer View
None HER2-positive Breast Cancer View
None Recurrent Breast Cancer View
None Stage IA Breast Cancer View
None Stage IB Breast Cancer View
None Stage II Breast Cancer View
None Stage IIIA Breast Cancer View
None Stage IIIB Breast Cancer View
None Stage IIIC Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None pre-operative View
None neo-adjuvant View
None triple negative View
None HER2 positive View
None hormone receptor positive View
None breast View
None Carboplatin View
None Nab-paclitaxel View
None Trastuzumab View
None Bevacizumab View
None Inflammatory View